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Abstract
Background: Telehealth solutions can improve the safety of ambulatory chemotherapy, contributing to the maintenance of
patients at their home, hence improving their well-being, all the while reducing health care costs. There is, however, need for a
practicable multilevel monitoring solution, encompassing relevant outputs involved in the pathophysiology of chemotherapy-induced
toxicity. Domomedicine embraces the delivery of complex care and medical procedures at the patient’s home based on modern
technologies, and thus it offers an integrated approach for increasing the safety of cancer patients on chemotherapy.
Objective: The objective was to evaluate patient compliance and clinical relevance of a novel integrated multiparametric
telemonitoring domomedicine platform in cancer patients receiving multidrug chemotherapy at home.
Methods: Self-measured body weight, self-rated symptoms using the 19-item MD Anderson Symptom Inventory (MDASI),
and circadian rest-activity rhythm recording with a wrist accelerometer (actigraph) were transmitted daily by patients to a server
via the Internet, using a dedicated platform installed at home. Daily body weight changes, individual MDASI scores, and relative
percentage of activity in-bed versus out-of-bed (I<O) were computed. Chemotherapy was administered according to the patient
medical condition. Compliance was evaluated according to the proportions of (1) patient-days with all data available (full) and
(2) patient-days with at least one parameter available (minimal). Acceptability was assessed using the Whole Systems Demonstrator
J Med Internet Res 2016 | vol. 18 | iss. 11 | e305 | p.1http://www.jmir.org/2016/11/e305/
(page number not for citation purposes)
Innominato et alJOURNAL OF MEDICAL INTERNET RESEARCH
XSL•FO
RenderX
Service User Technology Acceptability Questionnaire. Linear discriminant analysis was used to identify the combination of
parameters associated with subsequent unplanned hospitalization.
Results: A total of 31 patients (males: 55% [17/31]; World Health Organization Performance Status=0: 29% (9/31); age range:
35-91 years) participated for a median of 58 days (38-313). They received a total of 102 chemotherapy courses (64.7% as
outpatients). Overall full compliance was 59.7% (522/874), with at least one data available for 830/874 patient-days (95.0%),
during the 30-day per-protocol span. Missing data rates were similar for each parameter. Patients were altogether satisfied with
the use of the platform. Ten toxicity-related hospitalizations occurred in 6 patients. The combination of weighted circadian function
(actigraphy parameter I<O), body weight change, and MDASI scores predicted for ensuing emergency hospitalization within 3
days, with an accuracy of 94%.
Conclusions: Multidimensional daily telemonitoring of body weight, circadian rest-activity rhythm, and patient-reported
symptoms was feasible, satisfactory, and clinically relevant in patients on chemotherapy. This domomedicine platform constitutes
a unique tool for the further development of safe home-based chemotherapy administration.
(J Med Internet Res 2016;18(11):e305)   doi:10.2196/jmir.6303
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Introduction
Incremental advances in the treatment of cancer are responsible
for its progressive transformation into a chronic condition, with
a similar level of impact on the individual patients’ quality of
life, health, and well-being as other chronic diseases [1-3].
However, health care providers have not kept pace in developing
the design of their management packages for cancer patients to
fit the model of care for chronic diseases [1,2]. An important
aspect of the chronic diseases model of care is delivery of
treatment and review of symptoms assessed in the patient’s
home and usual environment [4-8]. To best achieve this goal in
cancer patients receiving often complex and toxic multidrug
chemotherapy, it is important that the care model integrates the
need for adequate safety [4,9,10]. Thus, an oftentimes complex
compendium of procedures given to home-dwelling patients
might be required [11]. Consequently, current practice usually
involves chemotherapy administration at least partly within the
hospital setting either as inpatient or outpatient, which can affect
patient’s quality of life and increase the financial burden on
patients and national health systems [5,9]. However, the
integrated home care and support proposed with the
domomedicine approach could offer an alternative to the present
care system [12]. Domomedicine is defined as all procedures
and care, sometimes complex, given at the patient’s home or in
his or her social and professional activities, at least comparable
in quantity and quality to those delivered in hospital, based on
modern technologies, and it aims at promoting medical progress
[12].
Improvements in treatment safety and patient well-being have
been the mainstay for the development of the delivery methods
that enable tailoring chemotherapy delivery according to
circadian clocks in cancer patients. Toward this goal, cancer
chronotherapy protocols use dedicated multichannel
programmable-in-time pumps [13,14]. Thus, chronotherapy
usually involves the chronomodulated delivery of
chemotherapeutic agents according to circadian rhythms in
nonhospitalized patients [13,15]. Doublet and triplet
chronomodulated regimens have been safely administered at
the patient’s home, resulting in improved tolerability and
efficacy [16-19].
Recent progress in information and communication technologies
can provide health care professionals with continuous data flow
on symptoms, quality of life, toxicity, behavior, and circadian
function from remote patients remaining within their own
environment [7]. Toward this goal, we integrated daily
telemonitoring of multidimensional objective and subjective
parameters into a dedicated electronic home-based platform
connected to the oncology department via a central server. We
assessed the feasibility of such an approach and its acceptability
in the clinical setting of advanced patients receiving multidrug
chronomodulated chemotherapy at home. The clinical relevance
of this domomedicine patient-centered system was further
evaluated to provide a first estimate of its ability to predict
unplanned emergency hospitalizations. The study was conducted
within the framework of the inCASA European project
(ICT-PSP). Its overall goal was the development of
citizen-centric technologies and a service network to improve
the health condition and daily life of patients suffering from a
chronic disease, thus minimizing hospitalizations.
Methods
Patients and Setting
Patients aged more than 18 years with any cancer type requiring
chemotherapy for at least one month were screened for the study
at the Chronotherapy Clinics in the Medical Oncology
Department of Paul Brousse Hospital in Villejuif, France.
Eligibility further required the availability of an Internet
connection at home and signed written informed consent. The
inCASA electronic platform and the related equipment were
installed at the home of each registered patient for a minimum
of 30 days. The platform was connected to the Internet Protocol
network. Each patient was instructed on how to use the platform
for the daily transfer of biomedical data, and was given a form
with telephone contacts information for technical or
health-related issues.
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While on study, patients could receive either conventional
chemotherapy or chronotherapy according to medical decision.
World Health Organization (WHO) Performance Status (PS)
score was estimated for all patients before each treatment to
support medical decision. WHO PS is a 0-5 score (0 indicating
perfect health and 5, death) used to quantify cancer patients’
well-being and functional status [20]. All conventional
treatments were administered in hospitalization or in outpatient
clinics. Chronotherapy was delivered using a multichannel
programmable pump (Melodie, Domocare, Montmirail, France)
at home or during hospitalization, according to patient
preference or medical decision.
The study was approved by the local institutional review board
and conducted according to the Declaration of Helsinki [21].
Each patient signed a written informed consent form.
Technical Equipment
The inCASA platform was composed of (1) a touch screen
computer (ASUS Eeetop ET1611, ASUSTEK, Taipei, Taiwan)
equipped with the SARA software (Telefonica Investigacion y
Desarrollo SA, Granada, Spain); (2) a body weight scale
(UC321-PBT, A&D Medical, San Jose, CA, USA), which was
connected to the computer via Bluetooth through the SARA
application; and (3) a wrist-watch accelerometer (actigraph)
(Micro MotionLogger, Ambulatory Monitoring Inc, Ardsley,
NY, USA), whose collected data on wrist accelerations (per
1-min epoch) were transmitted via an infrared USB dongle
connected to the computer (Figure 1a).
The SARA software included an electronic version of the MD
Anderson Symptom Inventory (MDASI) questionnaire for
self-assessment of 13 frequent core symptoms and 6 items
assessing interference with activities of daily living. Daily
self-rated MDASI items, self-measured body weight, and 24-h
rest-activity records were automatically transmitted to a server
through the Internet via the SARA software and the LinkSmart
Middleware (Figure 1b).
Figure 1. inCASA platform elements: (a) patient’s equipment (computer, scale, and actigraph); (b) information system technical architecture.
Study Design and Remote Monitoring Protocol
Patients were instructed to weigh themselves each morning, fill
out the on-screen MDASI questionnaire each evening,
continuously wear the wrist actigraph, and download the data
in the evening, before or after completing the questionnaire. All
the data were then transmitted daily via the Internet to the
secured central server. They could be securely accessed anytime
by the oncology nursing or medical staff with a dedicated
graphical display (Figure 2). The per-protocol recommended
study duration was 30 days for each patient. Patients were asked
to extend the duration of their participation to the study for
further 30 days or more, depending upon their wishes and
platform availability.
Patients were asked to contact the hospital or their general
practitioner (GP) as they would have normally done in case of
a health concern. Nonetheless, in case of a lack of data
transmission for more than 24 hours, high symptom severity,
quick body weight loss, or apparent deterioration of the circadian
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activity pattern, the oncology nurse usually phoned the patient
and organized any appropriate intervention. This could involve
telephone reassurance, a home visit by a technician or a nurse,
a patient visit to the GP or to the oncologist, or an emergency
visit at the outpatient clinics or in hospitalization (Figure 2).
Figure 2. Outline of study design and remote monitoring procedures. Source of icons: pixabay.
Platform Use Compliance
The overall compliance to the platform was assessed by
calculating longitudinal individual patient-day reporting rates.
These were defined as the total number of days in which data
were obtained divided by the duration of the period during which
the platform was available for use for each participant. These
rates were calculated for each parameter (body weight, MDASI,
and actigraphy) separately, for at least one parameter per
patient-day, and for all 3 parameters together. Furthermore,
given the 3-day time frame for emergency hospitalization
prediction, we also calculated the percentage of patients with a
full set of data (actigraphy, body weight, and MDASI) available
at least once during a sliding window of 3 days. Longitudinal
analysis was performed during the initial 30 days (primary
endpoint), and for the following 30 days (on-study days 31–60),
whenever applicable.
The study did not include specific and structured questioning
about the reasons for missing data; however, during routine
consultations, the medical oncologists (PI, AU, MB, MH, JFM,
and FL) were encouraged to offhand discuss the noncompliance
issue with the patients.
Platform Evaluation
Participants rated their perception and satisfaction regarding
the service delivered using the Whole Systems Demonstrator
Service User Technology Acceptability Questionnaire (SUTAQ)
[22] at study completion.
Unstructured, narrative interviews of the hospital nurses
involved (RBD, VP, and MM) were performed by the main
study investigators (AA, PI, and FL) to evaluate their global
perception of the clinical relevance of the platform and
acknowledge specific issues.
Collected Data Analysis
The daily percentage of body weight change was calculated
with reference to baseline values obtained over at least three
days before the initial course of on-study chemotherapy. The
19 MDASI item scores were used without any predefined
threshold. The rest-activity pattern was analyzed using the
Action 4 software (Ambulatory Monitoring Inc). The dichotomy
index I<O was selected as being the most clinically relevant in
cancer patients, according to prior work [23-31]. I<O was
computed as the percentage of activity epochs when in-bed,
whose values were lower than the median level of activity when
out-of-bed [32]. A normal dichotomy index is one approaching
100%, indicating restful sleep in bed at night and regular and
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lively activity during the day, out of bed. Values of I<O in
healthy controls are rarely <98% [32,33]. Here, I<O was
calculated over 72 h, with 3-day sliding windows, throughout
the whole time series in each patient.
Descriptive analyses were performed for the overall distribution
and individual longitudinal patterns of body weight change, of
the 19 MDASI items separately, and of I<O.
Emergency Hospitalization Prediction
Time series were analyzed using Matlab (The Mathworks,
Natick, MA, USA), and ranked for relevance regarding
prediction of emergency hospitalizations. First, handling missing
data in each of the 21 time series (19 MDASI items, body weight
loss, and I<O) from each patient were interpolated according
to their localization: missing data localized at the beginning (or
at the end) of the time series were assumed as having the value
of the first (or the last) measured value, respectively; a linear
interpolation was used to compute missing data within two
measured data segments. We initially tested several interpolation
approaches (bi-cubic, harmonic, likelihood, and principal
component analysis-based) for our sensitivity analyses, but the
final results were roughly similar to those using the simple linear
method (data not shown). Second, we calculated the dynamic
patterns of change over time by subtracting the parameter value
of each day from the average of the same parameter on the three
previous days. Finally, linear discriminant analysis (LDA) was
used on these computed values to determine the combination
of parameters whose 3-day dynamic patterns best predicted for
an unplanned hospitalization (target event). The predefined time
frame for prediction was set at the 3 days preceding each
emergency hospitalization event.
Results
Study Patients’ Cohort
A total of 52 patients were screened as potentially eligible from
October 2011 to August 2013 (Figure 3). Eight were not
registered for technical reasons, and 7 declined participating.
One patient was repeatedly hospitalized for prolonged spans
because of acute cancer progression just after inclusion and
could not provide any data. Five patients participated in the
prepilot phase. The results reported here regard the 31 patients
included in the pilot phase.
Patients aged 35-91 years (median: 61 years) participated in the
study for a median duration of 58 days (range: 38-313 days).
Most of them were treated for colorectal, pancreatic, or breast
cancer (Table 1). The majority of patients had undergone prior
surgery and received prior chemotherapy. A total of 102
chemotherapy courses were administered to the 31 patients
while on-study. Six patients (19%) received 20 courses of
conventional chemotherapy at the hospital (20% of courses).
The remaining 25 patients (81%) were treated with 82 courses
of chronomodulated chemotherapy, of which 66 (80%) were
administered at home.
Figure 3. Study flowchart (Consort diagram).
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Table 1. Clinical features of the study population.
n (%)Patient characteristics
Gender
17 (55)Male
14 (45)Female
Age (years)
4 (13)35-45
4 (13)45-55
11(36)55-65
5 (16)65-75
5 (16)75-85
2 (6)85-95
61 (35-91)Median (range)
World Health Organization performance status
9 (29)0
11(36)1
2 (6)2
2 (6)3
7 (23)Not available
Primary tumor site
8 (26)Colon
4 (13)Rectum
9 (29)Pancreas
5 (16)Breast
2 (7)Prostate
1(3)Lung
1(3)Liver
1(3)Ovary
Number of metastatic sites
7 (23)0
24 (77)1
Comorbidities
24 (78)None
5 (16)Diabetes
1 (3)Hepatitis B
1(3)Chronic heart failure
Prior surgery for
3 (10)None
20 (64)Primary tumor
8 (26)Metastases
Prior chemotherapy
3 (9)No prior chemotherapy
11 (36)Adjuvant only
1 (3)Metastatic only
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n (%)Patient characteristics
16 (52)Both
Number of prior chemotherapy protocols for metastatic disease
13 (42)None
4 (13)One
12 (39)Two or more
2 (6)Unknown
Chronotherapy protocol while on inCASA
25 (81)Total number
13 (42)ChronoIFLO4a
2 (7)Other chrono triplets
10 (32)Other chrono doublets
Conventional chemotherapy protocol while on inCASA
6 (19)Total number
1 (3)Triplet
2 (6)Doublet
3 (10)Monotherapy
Protocol courses given on inCASA
102 (100)Total number
66 (65)At home
36 (35)At hospital
3 (1-14)Median number per patient (range)
aChronoIFLO4 is the chronomodulated combination of irinotecan, oxaliplatin, 5-fluorouracil, and leucovorin [19].
Study Compliance
During the initial 30-day period (per-protocol), patients provided
complete daily data (body weight, MDASI, and actigraphy) for
a total of 522 days out of the 874 theoretical patient-day data
(930 total minus the 56 days of elective or emergency
hospitalizations). Hence, overall full compliance was 59.7%.
Individual general compliance for each parameter was as
follows: 81.7% (714/874) for body weight, 78.1% (683/874)
for MDASI, and 74.7% (653/874) for actigraphy. At least one
parameter for each patient-day was available in 95.0% (830/874)
cases. Moreover, at least one complete set of daily data for the
3 parameters was available at least once every 3 days in 77.2%
of the cases. Altogether, compliance remained rather good and
stable over the per-protocol 30-day span (Figure 4). However,
in the longer term (days on study 31-60), data availability
decreased for those patients who opted for continuing the study
beyond the per-protocol time span (Figure 4). In particular, over
this subsequent 30-day span, complete daily data were provided
for 38.7% (264/683) patient-days. Respective figures were
64.4% (440/683) for body weight, 61.3% (419/683) for MDASI,
62.1% (424/683) for actigraphy, and 83.0% (567/683) for at
least one of them. Finally, 55.1% of patient-days had at least
one complete set of data at least once every 3 days, during days
on study 31-60 (Figure 4).
Individual patient compliance (available out of theoretical data)
ranged from 0% to 85.7%, with a median of 56.3%.
The most common reasons for missing data, outside planned or
emergency hospitalizations (125 patient-days), were informally
reported to be technical problems, out-of-home trips, and patient
forgetting or feeling too sick.
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Figure 4. Long-term longitudinal compliance rates. The red curve shows the percentage of available data per day (MDASI counted as one), and the
blue one, the percentage of patients with all data (actigraphy, body weight, and MDASI) available at least once during 3 days. The solid curves plot the
initial 30 days (per-protocol period), and the dashed ones, the following 30 days (day 31-60). MDASI: MD Anderson Symptom Inventory.
Platform Evaluation
Fifteen patients completed the SUTAQ questionnaire, which
was offered at mid study course to 22 patients (results detailed
in Table 2). The general satisfaction rate was 84%. The system
was perceived to enhance care for 80% of the patients; 87% of
the participants indicated that it did not interfere with their life
or privacy. However, 67% of them considered that it could not
be used as a substitution for the current health care. No patient
in the study offhand recounted any major issues appreciated in
the platform to the physicians, nurses, or technicians. Whenever
specifically questioned, patients expressed generally positive
comments on the platform, as a usable additional health care
tool, in agreement with the subgroup completing SUTAQ.
All 3 surveyed hospital nurses involved in this study
spontaneously reported the perception that the system globally
improved the follow-up of the health condition of the patients,
in comparison to the current standard procedure. They also
acknowledged, nevertheless, that some technical problems
interfered with their experience, especially when recurring in
the same patient, and proposed that dedicated personnel ought
to be allocated to such domomedicine task. Finally, the system
usability was altogether recognized by the 3 nurses
independently as operational for larger-scale deployment.
Table 2. Perception and satisfaction resultsa.
SUTAQb items
SatisfactionKit as substitu-
tion
Care person-
nel concerns
Privacy and dis-
comfort
Increased accessi-
bility
Enhanced careOutcomes
4.23.13.64.23.03.8Mean item score
84%62%72%83%60%77%General satisfaction with the item
1451013712Number of patients satisfied with the
item
93%33%67%87%47%80%Percentage of patients satisfied with the
item
aResponses to the SUTAQ questions were measured using a 5-point Likert scale.
bSUTAQ: Service User Technology Acceptability Questionnaire.
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Table 3. Distribution of objective and subjective collected data during the study.
Range (min to max)1st; 3rd quartilesMedianParameters
Objective  
–10.5 to 6.0–2.0; 0.9–0.4Body weight change (%) 
82.5 to 10096.6; 99.198.3I<O (%)
Subjective  
MDASIa symptom items   
0 to 100; 42Pain 
0 to 102; 54Fatigue
0 to 100; 20Nausea
0 to 90; 42Disturbed sleep
0 to 101; 53Distress
0 to 91; 52Shortness of breath
0 to 80; 21Problem with remembering things
0 to 100; 52Lack of appetite
0 to 80; 42Drowsiness
0 to 100; 51Dry mouth
0 to 90; 52Sadness
0 to 100; 00Vomiting
0 to 100; 31Numbness or tingling
MDASI interference items  
0 to 102; 54General activity 
0 to 90; 42Mood
0 to102; 65Work
0 to 90; 42Relations with others
0 to 101; 53Walking
0 to 102; 53Enjoyment of life
aMDASI: MD Anderson Symptom Inventory.
Descriptive Analysis of Collected Data
The quartiles and extreme values of body weight change, I<O,
and individual MDASI items for all patients throughout the
whole study span are shown in Table 3.
The dynamics of rest-activity patterns, computed I<O values,
body weight changes, and MDASI items scores are depicted
for 2 representative patients over 57 and 44 days, respectively
(Figure 5).
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Figure 5. Representative examples of the multidimensional data available for 2 patients over 57 (top) and 44 (bottom) monitoring days, respectively.
From left to right: first panels: actigraphy recording (midnight-centered double plot; Y-axis: activity counts per minute); second panels: corresponding
daily I<O values; third panels: daily body weight change; fourth panels: daily MDASI items (heat map; white represents missing values, blue through
yellow to red, increasing values from 0 to 10). Purple boxes represent the days during which chemotherapy was administered. In the bottom plot, the
red box represents the duration of an emergency hospitalization. MDASI: MD Anderson Symptom Inventory.
J Med Internet Res 2016 | vol. 18 | iss. 11 | e305 | p.10http://www.jmir.org/2016/11/e305/
(page number not for citation purposes)
Innominato et alJOURNAL OF MEDICAL INTERNET RESEARCH
XSL•FO
RenderX
Emergency Hospitalizations
An emergency hospitalization event occurred after 9.8%
(10/102) chemotherapy courses in 6 patients (19%). Thus, 5
participants underwent a single unplanned hospitalization, and
1 patient was hospitalized 5 times. Table 4 details the most
relevant characteristics of these hospitalization events.
Appropriate symptomatic treatment was administered as
indicated, with discharge at home in all cases.
Table 4. Clinical features of patients involved and events regarding unplanned hospitalizations.
n (%)Patient characteristics
 
 Gender
2 (33)Male
4 (67)Female
60 (52-91)Age in years, median (range)
Chemotherapy protocols followed by unplanned hospitalization, n=10
 Type of delivered chemotherapy
9 (90)Chronotherapy
1 (10)Conventional chemotherapy
Location of treatment delivery
5 (50)At home
5 (50)At hospital
Hospitalizations, n=10  
 Number per patient
5 (83)Only one hospitalization
1 (17)More than one hospitalization
6 (2-9)Hospital stay (days), median duration (range)
 Causes
5 (50)Gastrointestinal symptoms with general physical deterioration
3 (30)Febrile neutropenia
1 (10)Sepsis
1 (10)Asthenia with poor general condition
Early Warning Signals Predicting Emergency
Hospitalizations
A global decrease in average daily rest-activity I<O values was
observed over the 2 weeks preceding an unplanned
hospitalization (Figure 6a). No such trend was obvious for body
weight changes (Figure 6b). Some patient-reported symptoms,
such as interference with work or lack of appetite, appeared to
worsen on average before an unplanned admission, while others,
such as problem with remembering things, did not display
congruous changes over the same time span (Figure 6c).
LDA identified the model with the relative weights for the
dynamic patterns in circadian rest-activity I<O parameter, body
weight change, and MDASI scores, which best predicted for a
subsequent emergency hospitalization during the following 3
days (Table 5). Testing the model on the whole dataset (initial
30 days for learning and additional 30 days for validation)
yielded a sensitivity of 55.5%, a specificity of 94.6%, a positive
predictive value of 12.7%, and a negative predictive value of
99.3% (Table 6). Hence, global accuracy was 94.0%. Sensitivity
analyses confirmed the results of the main predictive model,
with the highest loading weight assigned to I<O and a cluster
of MDASI items connected to interference with relations, daily
activities, and appetite.
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Table 5. Coefficients of all the 21 items (ranked) of the final predictive linear discriminant analysis (LDA) model.
CoefficientParameter
–0.945Shortness of breath
0.772I<O
0.634Relations with others
–0.492Work
0.473Disturbed sleep
–0.466Drowsiness
0.435Sadness
–0.351Distress
–0.335Problem with remembering things
0.283Vomiting
0.221Numbness or tingling
0.198Mood
0.153General activity
–0.136Nausea
–0.128Enjoyment of life
0.097Dry mouth
0.089Walking
–0.089Lack of appetite
0.065Pain
–0.025Body weight change
–0.009Fatigue
Table 6. Confusion matrix regarding prediction of unplanned hospitalization.
Actual eventPatient/day
NoYesPredicted
6910Yes
12038No
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Figure 6. (a) Average (and standard error of the mean) daily I<O values, (b) body weight change, (c) and 3 selected MDASI items in the 2 weeks
preceding unplanned hospitalizations (n=10). The yellow bar highlights the 3 days preceding the emergency hospitalization, used for the predictive
analysis (LDA). MDASI: MD Anderson Symptom Inventory, LDA: linear discriminant analysis.
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Discussion
Main Results
Continuous telemonitoring of circadian rest-activity rhythm,
jointly with daily body weight and self-reported symptoms, was
implemented for the first time in the home of patients receiving
chemotherapy for advanced cancer. The inCASA domomedicine
platform was found to be adequate for such purpose, since it
was well accepted by the patients and provided an unprecedented
amount of multidimensional data over prolonged time spans.
Furthermore, the integration of the subjective and objective data
translated into accurate information able to predict subsequent
emergency hospitalization (Table 6). Thus, such novel telehealth
system carries out a number of potential clinical applications.
Comparison With Prior Studies
The inCASA platform was home located and Web-based, but
it did not require to log-in, in contrast to other telehealth studies
[5,34-36]. The multiparameter monitoring performed here was
not limited to patient-reported outcomes, as it is usually the case
[5,34,35,37]. In contrast, teletransmitted parameters also
included objectively measured body weight and wrist activity
pattern (Figure 2). This required technical innovations for
minimizing patient discomfort and maximizing compliance.
Both parameters were chosen on the basis of previous results
relating altered circadian rest-activity rhythm to poor outcomes
[23,25,27], body weight loss to circadian disruption [24], and
both parameters to poor survival outcome on chronotherapy
[38]. The proper tracking of the dynamic changes in these
parameters entailed the need for daily measurements, whereas
other authors have proposed evaluations of symptoms and
quality of life once a week or at each clinic visit
[4,5,34,35,39,40]. With an overall 59.7% per-protocol
compliance rate, and with 95% of the days having at least one
data, our study demonstrates the feasibility of cancer patients’
empowerment for gathering and teletransmitting both subjective
and objective health-related data. Moreover, the compliance
appeared altogether stable over time during the per-protocol
span (Figure 4), inferring possible long-term use. However, the
sustainability of such platform in daily clinical practice cannot
be definitely foretold with this study, as it did not include
cost-effectiveness analysis or payment stakeholders’
involvement.
Limitations
Although the platform workflow was well accepted by patients
altogether, some technological aspects could be refined to
increase both comfort and convenience, thus further improving
compliance rates in view of a prolonged use. For example,
circadian rest-activity rhythm data could be automatically and
seamlessly transmitted to the home-based platform, and
thereupon to the central server, resulting in less end-user
manipulations. Additionally, hospital nurses indicated the
positive impact of timely technical support for the
implementation of this patient-centered approach, confirming
previous report [41]. On some occasions, patients were unable
to provide data due to traveling away from home, suggesting
the relevance of lightweight mobile systems for further
developments. Thus, a handheld computer was used to record
self-reported and objective measures in oncologic outpatients
with satisfactory acceptance and reliability [39]. Similarly,
smartphone-based apps have been successfully tested for
frequent symptom evaluation and toxicity management in
patients on chemotherapy [9,42]. Such mobile technology could
further enhance long-term compliance, as suggested [35,37].
However, certain features of the solution will need to be
modified, including the addition of a log-in component for
authentication on the main mobile device, required to be
connected to the Web via secure wireless network for data
transfer protocol, and the possibility of manually adding body
weight. Nonetheless, the wearable device, the interface of the
main technical equipment, the server-based system, and the
remote monitoring procedures will allegedly not require
significant modifications.
Perspectives
Notwithstanding these amendable technical issues, this study
identified, for the first time, a combination of subjective and
objective parameters whose dynamics predicted the occurrence
of emergency hospitalization within 3 days from the event with
an accuracy of 94%. Thus, the integrated multiparametric
assessment, including body weight and circadian rest-activity
rhythm jointly with subjectively rated symptoms, provided a
novel framework for the early detection of severe adverse events
that will require hospital admission within 3 days. These data
allow foreseeing the timely triggering of proactive interventions
to improve the safety of treatment administration at home while
potentially reducing the financial burden on health care providers
[43,44]. Indeed, less frequent emergency room visits were
described from adequate nurse-initiated response during routine
cancer care involving weekly remote monitoring of self-reported
symptoms [36].
This pilot study was mainly observational; hence, no predefined
decisional pathway or procedures were implemented according
to telemonitored data. Notwithstanding, common sense and
prudence led the investigators to off-protocol contact patients
in case of missing data, mainly for reasons not requiring medical
attention, or, less often, in case of parameter deterioration
(Figure 2). In this study we could not quantify the benefit to the
patients related to early interventions prompted by observed
alterations in I<O, body weight change, or MDASI items, but
it was probably realistic to assume that, in some cases,
contacting the patient and eliciting a rapid and opportune
medical care response could have avoided more severe
outcomes, even if these procedures were informally executed
(Figure 2).
Such hypothesis of patient benefit from a telemonitoring-guided
proactive intervention is being tested within a multicenter
domomedicine French study, using a second-generation platform
(PiCADo) [12]. The study involves patients receiving multidrug
chronotherapy at home, using the acquired expertise and the a
posteriori predictive model derived from the current study.
Moreover, the forecasting analysis applied in the current study
provides an evolving methodological framework, whose
prediction ability improves through learning based on data
enrichment stemming from forthcoming studies.
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Finally, besides low I<O that defines altered circadian rhythms,
the MDASI items most strongly associated with subsequent
unplanned hospitalization have been linked to circadian
disruption (fatigue, appetite loss, and poor physical, social, and
role functioning) [23,24,26,27,45]. Therefore, these findings
bolster the clinical relevance and warrant the implementation
of circadian rhythms monitoring in medical oncology [15].
Conclusions
The inCASA solution allowed monitoring not only of
patient-reported symptoms, but also of circadian rest-activity
patterns and of body weight in cancer patients on chemotherapy,
while they were at home. These unique and novel data provided
useful information to health care and social care professionals
for the follow-up of patient’s well-being. The ultimate
paramount benefit of this approach is the increased safety of
chemotherapy administration at home. In our experience, this
multidimensional telemonitoring represented an effective,
accurate, and refined tool for identifying patients at risk for
emergency hospitalization, allowing in the future the
development and timely triggering of preemptive, coordinated,
and befitting interventions to prevent such unplanned
admissions, within a domomedicine approach.
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